Patients who are receiving conventional therapy according to the MOH protocol.

Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy

COVID-19

LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.
Dose:
One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour

Licorice extract

Faculty of Medicine, Assiut University

Complementary Intervention for COVID-19

Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine

Conversion of RT-PCR indicates positive for novel coronavirus RNA to negative

Decrease number of patients that require respiratory support , management in the Intensive Care Unit (ICU) and need Mechanical Ventilation Support with endotracheal intubation.

A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum

Adel Gomaa

Professor of medical pharmacology

Egyptian Biomedical Research Network

Corona Virus Infection

SARS-CoV 2

Coronavirus

Coronavirus Infection

Treatment will be sprayed orally twice a day for the first 2 days in the treatment period

ArtemiC

Placebo

Hillel Yaffe Medical Center

Nazareth Hospital EMMS

Rambam Health Care Campus

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19

patient will be assessed using a scoring table for changes in clinical signs

Adverse events caused by the study drug will be assessed

MGC Pharmaceuticals d.o.o

Patients will be randomized in a manner of 2:1 for study drug (ArteminC) and Standard of Care to Placebo and Standard of Care.
Patient study period will last 2 weeks. During this time, patients will be monitored for adverse events.
There will be a follow up period (until hospital discharge) in order to check side effects and study drug efficacy

25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)

25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2

Renal Stones

AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma

AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)

Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)

Potassium Sodium Hydrogen Citrate

Mohamed Salim Ahmed Al-Marhoon

Treatment of Renal Stones With Frankincense (Luban)

Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial

The participants intolerance of the treatment or development of side effects that are not known complications of the presence of stones or new adverse reactions

boswellia ogadensis/antioksidantti

Complementary Intervention for COVID-19

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19

Treatment of Renal Stones With Frankincense (Luban)

Dietary Supplements and Periodontal Wound Healing

Täydellisin lääketieteellinen tietokanta tieteen tukemana